A5015112581- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- CRISPR and Genetic Engineering
- Cancer Immunotherapy and Biomarkers
- Ubiquitin and proteasome pathways
- Chemokine receptors and signaling
- Lipid metabolism and disorders
- Colorectal Cancer Treatments and Studies
- Genomics and Chromatin Dynamics
- HIV/AIDS drug development and treatment
- Immune Cell Function and Interaction
- Apelin-related biomedical research
- Hormonal Regulation and Hypertension
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
Inserm
2018-2023
Nantes Université
2018-2023
Centre National de la Recherche Scientifique
2020-2023
Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers
2021-2023
Université d'Angers
2018-2021
Recently, the inhibitory CD94/NKG2A receptor has joined group of immune checkpoints (ICs) and its expression been documented in NK cells CD8+ T lymphocytes several cancers some infectious diseases. In colorectal cancer (CRC), we previously reported that NKG2A+ tumor-infiltrating (TILs) are predominantly αβ CD94 overexpression and/or ligand HLA-E were associated with a poor prognosis. This study aimed to thoroughly characterize TIL subpopulation document impact NKG2A on anti-tumor responses...
Background Genome editing offers unique perspectives for optimizing the functional properties of T cells adoptive cell transfer purposes. So far, PDCD1 has been successfully tested mainly in chimeric antigen receptor (CAR-T) and human primary cells. Nonetheless, patients with solid tumors, effector memory specific tumor antigens remains a relevant option, use high avidity deficient programmed death-1 (PD-1) expression is susceptible to improve therapeutic benefit these treatments. Methods...
Among Immunotherapeutic approaches for cancer treatment, the adoptive transfer of antigen specific T cells is still a relevant approach, that could have higher efficacy when further combined with immune check-point blockade. A high number trials been performed in metastatic melanoma, due to its immunogenic potential, either polyclonal TIL or antigen-specific populations. In this setting, extensive characterization cell functions and receptor diversity infused required, notably monitoring...
Among glucocorticoids (GCs), dexamethasone (Dex) is widely used in treatment of multiple myelomas. However, despite a definite benefit, all patients relapse. Moreover, the molecular basis glucocorticoid efficacy remains elusive. To determine genomic response to Dex myeloma cells, we generated bulk and single-cell multi-omics data high-resolution contact maps active enhancers target genes. We show that minority receptor-binding sites are associated with enhancer activity gains, increased...
Glioblastoma is one of the most lethal forms adult cancer, with a median survival ∼15 mo. Targeting glioblastoma stem-like cells (GSCs) at origin tumor formation and relapse may prove beneficial. In situ, GSCs are nested within vascular bed in tight interaction brain endothelial cells, which positively control their expansion. Because notably addicted to apelin (APLN), sourced from surrounding stroma, APLN/APLNR nexus has emerged as druggable network. However, how this signaling axis...
Abstract Glucocorticoids (GC) effects occur through binding to the GC receptor (GR) which, once translocated nucleus, binds response elements (GREs) activate or repress target genes. Among GCs, dexamethasone (Dex) is widely used in treatment of multiple myeloma (MM), mainly combination regimens. However, despite a definite benefit, all patients relapse. Moreover, while efficacy can be largely attributed lymphocyte-specific apoptosis, its molecular basis remains elusive. To determine...